Article info
PDFMultiple sclerosis
Research paper
Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
- Correspondence to Professor Tomas Olsson, Department of Clinical Neurosciences, Karolinska Institute, Centre of Molecular Medicine, L8.04, Karolinska Hospital (Solna), Neuroimmunology Unit, Stockholm 171 76, Sweden; Tomas.Olsson{at}ki.se
Citation
Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publication history
- Received November 18, 2013
- Revised February 14, 2014
- Accepted February 24, 2014
- First published March 21, 2014.
Online issue publication
December 12, 2019
Article Versions
- Previous version (12 December 2019).
- Previous version (12 December 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/